40+ Presentations from Top Biopharma

Characterization of Challenging Protein Complexes—Mixture of Soluble and Insoluble Aggregates
Xue (Snow) Yang, PhD, Senior Scientist, AbbVie, Inc.

Not All Bispecifics Are Created Equal
Chen Zhou, PhD, Principal Research Scientist, Biologics Drug Product Development, AbbVie Bioresearch Center

Frozen State Protein Aggregation and Its Impact on Biologic Process Development
Bharat Jagannathan, PhD, Principal Scientist, Attribute Sciences, Amgen Inc.

MAD7 Nuclease Facilitates Cutting and Site-Specific Integration in CHO Genome
Jonathan Diep, PhD, Principal Scientist, Cell Line Development, Amgen, Inc.

High Particle Numbers of Aggregated Biotherapeutics are a Key Factor for Inducing an Immunogenic Response In Vitro, In Vivo, and In the Clinic
Joseph R Cohen, Principal Scientist, Attribute Sciences, Amgen Inc.

Developing a Highly Flexible Mass Spectrometry Platform for Comprehensive Characterization of Large Molecule Therapeutics
Yoan Machado, PhD, Scientist, Molecular Analytics, Amgen

Characterization of Forced Degraded Antibodies Using Advanced Analytics for Higher-Order Structure Assessment
Nithya Srinivasan, PhD, Principal Scientist, Amgen

Protein Production from HEK293 Cell Line-Derived Stable Pools with High Protein Quality and Quantity to Support Discovery Research
Songyu Wang, PhD, Senior Scientist, Protein Technologies Group, Amgen

Improving Anti-Tumor Activity with Bispecific Antibody Drug Conjugates
Frank Comer, PhD, Director, Tumor Targeted Delivery, Early Oncology R&D, AstraZeneca

Moving Functional Assays Higher in the Screening Cascade
Elizabeth England, PhD, Associate Director, Biologics Engineering, AstraZeneca

Enhancement of Antibody Thermostability and Affinity by Computational Design in the Absence of Antigen
Gilad Kaplan, PhD, Associate Director, Biologics Engineering, AstraZeneca

Connecting the Lab to the Machine: A Retrospective Analysis and Prospective Evaluation
Michael S. Marlow, PhD, Director Biologics CMC Research, Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.

Dual Detection Approach for Charge Variant Analysis of Monoclonal Antibody Combination Products Using Imaged Capillary Isoelectric Focusing (iCIEF)
Xue (Shelly) Li, Associate Director, Biologics Development, Bristol Myers Squibb Co.

Manufacturability Assessment of Bispecifics in the Preclinical Space
Ronan Kelly, PhD, Director, Protein Expression & Purification, Eli Lilly & Co.

A Comparative Study of Antibody Structure Prediction Methods through Molecular Dynamics Simulations
Darcy Davidson, PhD, Structural and Computational Biologist, Genentech

Lab-in-the-Loop ML for Accelerating Antibody Discovery, Optimization, and de novo Design
Vladimir Gligorijević, Senior Director, AI/ML, Prescient Design, Genentech

In vitro Characterization of Molecular Binding Interactions: New Development in Obtaining More Biologically Relevant Information
Xiangdan Wang, PhD, Senior Principal Scientist, BioAnalytical Sciences, Genentech, Inc.

Fc Effector Function Characterization of T Cell-Dependent Bispecifics
Zhaojun Yin, Principal Scientist, BioAnalytical Sciences gRED Development Sciences, Genentech

Maximizing Effectiveness of Protein Expression Screening for Drug Discovery
Inna Zilberleyb, Scientist IV, Biomolecular Resources, Genentech, Inc.

High-Throughput Structural Modeling of Monoclonal and Multispecific Antibodies
Daniel Keri, PhD, Research Scientist, Protein Engineering and Design, Gilead Sciences

Immunogen and Screening Protein Productions to Develop a Specific and Sensitive Antibody for Viral Coat Protein Detection
Christa Cortesio, PhD, Director, Protein Science, Protein Biochemistry & Analytics Core, Kite Pharma

Development and Scale-Up of rVSV-SARS-CoV-2 Vaccine Process Using Single Use Bioreactor
Lizz Carey, Senior Scientist, Vaccine Process Development, Merck

Characterizing Silicone Oil-Induced Protein Aggregation with Stimulated Raman Scattering Imaging
Xi Zhao, PhD, Senior Scientist, Sterile and Specialty Products, Merck

Optimizing Early Candidate Screening and Accelerating Cell Line Development
Zorica Dragic, PhD, Director, Cell Line Screening and Development, Novartis Pharma AG

Modulating PlasmaHalf-Life and formulation Stability of Peptide Therapeutics
Dennis Åsberg, PhD, Senior Scientist, Biophysics and Injectable Formulation, Novo Nordisk A/S, Denmark

Application of SEC-MALS for Measuring Multiple CQAs for rAAV Gene Therapies
Sharee Adams-Hall, Senior Scientist, Pharmaceuticals, Pfizer Inc.

Managing Parallel Protein Production Workflows in a Matrixed Organization
Oleg Brodsky, Senior Principal Scientist, Structural Biology & Protein Sciences, Pfizer Inc.

Synthetic Biology and AI—How These Tools Enable a New Frontier When Combined with the Manufacturing and Design Capabilities of RNA
Charles Jones, PhD, Senior Director, mRNA Commercial Strategy & Innovation, Pfizer Inc.

A High-Fidelity, Dual Site-Specific Integration System in CHO Cells by a Bxb1 Recombinase
Yifeng Xu, PhD, Senior Scientist, Cell Line Development Bioprocess R&D, Pfizer Inc.

Comprehensive Glycoproteomic Characterization of Different Host Cell Lines and Biotherapeutics
Qiong Wang, PhD, Senior Scientist, Mammalian Expression, Pfizer

Combining a Biparatopic MET Antibody with a Tubulin Inhibitor for a One-Two Punch to Treat NSCLC
Thomas Nittoli, PhD, Senior Director, Therapeutic Proteins, R&D Chemistry, Regeneron Pharmaceuticals, Inc.

Intensification of Downstream Manufacturing of rAAV Using Single Pass Tangential Flow Ultrafiltration
Garima Thakur, PhD, Process Development Engineer III, Viral Production Core, Regeneron Pharmaceuticals, Inc.

Combination Strategies to Enhance Anti-Tumor T Cell Response
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.

LC-MS-Based Product Quality of Antibody-Based Therapeutics Direct from Cell Culture Supernatants
Juan José Bonfiglio, PhD, Science and People Lead, Mass Spectrometry, Roche, Germany

Automating Analytical Characterization of Next-Generation Protein Therapeutics
Miroslav Nikolov, PhD, Senior Scientist & Laboratory Head, Roche

Adsorption of Monoclonal Antibodies to Medical Surfaces
Rosa Alvarez-Palencia, CIFRE Research Scientist, Biologics Drug Product Development, Sanofi

Charge Variant and Succinimide-Isomerization Induced & Rescued Potency of a Common Light Chain Bispecific Antibody
Bertie Chi, PhD, Senior Scientist, CMC Characterization & Analytical Development, Sanofi

Towards Biologics by Design: Computational Optimization of Multispecific Protein Therapeutics
Norbert Furtmann, PhD, Head, Computational & High-Throughput Protein Engineering, Large Molecule Research, Sanofi

Harnessing Emerging Technologies to Develop Optimal Subclonal Host Cell Line for AAV Production
Amit Mathur, PhD, Senior Scientist, Genomic Medicine Unit, Sanofi